MEDIUM confidence: 100% data completeness, but the composite (44) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Avg target $185 (last qtr, 43 analysts) → $227 (last mo, 6) (+22.7%).
Buy-rated share 77% → 77% over ~3 months (+1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $0.27 | $0.28 | +3.7% |
| Mar 2026 | $0.27 | $0.28 | +2.8% |
| Dec 2025 | $0.23 | $0.24 | +2.2% |
| Aug 2025 | $0.21 | $0.23 | +11.7% |
| Jun 2025 | $0.20 | $0.18 | -9.7% |
| Mar 2025 | $0.21 | $0.26 | +20.2% |
| Nov 2024 | $0.20 | $0.23 | +13.6% |
| Aug 2024 | $0.24 | $0.26 | +7.2% |
Net insider -$30.5M over 180 days (0 open-market buys, 100 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $1.5B— | $2.2B+54.4% | $3.1B+36.3% | $4.0B+29.4% | $4.8B+21.7% |
| EPS (dil.) | $-0.26— | $-0.20n/m | $0.09n/m | $-0.02-121.3% | $-0.16n/m |
| Free Cash Flow | $441M— | $675M+52.9% | $929M+37.7% | $1.1B+14.9% | $1.3B+22.7% |
| Gross Margin | 73.6% | 73.2%-0.4pp | 75.3%+2.1pp | 74.9%-0.3pp | 74.7%-0.3pp |
| Operating Margin | -9.8% | -8.5%+1.3pp | -0.1%+8.4pp | -3.0%-3.0pp | -6.1%-3.0pp |
| Net Margin | -16.2% | -8.2%+8.0pp | 2.9%+11.1pp | -0.5%-3.4pp | -3.4%-2.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 19.2%/yr (revenue basis).
Base free cash flow $1.1B (avg FY2024–FY2026; latest year $1.3B) · equity value $228.6B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 44 for CRWD indicates a neutral outlook, driven by a divergence between its long-term and short-term scores, with the latter being 17 points higher. The stock scores high on momentum, exhibiting strong momentum with a 106.4% return over the past year, but is dragged down by its value category, which is negatively impacted by its extremely high valuation multiples, including a P/E of -4726.9 and EV/EBITDA of 671.9. The growth category also contributes to the lower score, due to a significant decline in EPS growth, despite strong revenue growth of 21.7%.